| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 735.2 | 739.1 | 1328.9 |
| Other income | 59.2 | 77.8 | 61.7 |
| Total income | 794.4 | 816.9 | 1390.6 |
| Profit before exceptional items & tax | 185.6 | 144.1 | 571.9 |
| Profit before tax | 185.6 | 144.1 | 571.9 |
| Net profit | 206.5 | 269.0 | 480.3 |
| Operating margin | 23.4% | 17.6% | 41.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -57.00% |
|---|---|
| Net profit, quarter on quarter | -23.20% |
| Revenue, year on year | -44.70% |
| Operating profit, year on year | -75.20% |
| Operating profit, quarter on quarter | +90.60% |
NSE results filing, NSE: NATCOPHARM. Figures extracted from the filing.
Natco Pharma Ltd: key numbers
- Share price
- ₹839.30
- Market cap
- ₹15,033 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.1×Sector 50.4×
- Promoter holding
- 49.42%+0.00% QoQ
- FII holding
- 16.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Fund Raise of ₹1,279 Cr
Natco Pharma's board has approved a Rights Issue to raise ₹1,279.36 Crore. The company will issue 17,058,082 equity shares at ₹750 each in a 2:21 ratio.
- Value
- ₹1,279 Cr
Natco Pharma Capital Structure Change
Natco Pharma's board approved a Rights Issue of 1,70,58,082 shares aggregating to ₹1,279.36 Crore. The issue is priced at ₹750 per share with a 2:21 ratio.
- Value
- ₹1,279 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 25th September 2026 to finalise terms for its previously approved rights issue, including pricing and record date.
Natco Pharma Capital Structure Change
Natco Pharma has received in-principle approval from BSE and NSE for its upcoming Rights Issue of fully paid-up equity shares.
Natco Pharma Capital Structure Change
Natco Pharma proposes a Rights Issue of equity shares aggregating up to ₹1,300 Crore. The company has filed the Draft Letter of Offer for this capital raise.
- Value
- ₹1,300 Cr
Natco Pharma Fund Raise of ₹1,300 Cr
Natco Pharma board approved a rights issue of up to ₹1,300 crore face value ₹2 equity shares. The demerger scheme will be revised post-completion of the raise.
- Value
- ₹1,300 Cr